| PSA |
Report |
Core FFO per share (Q2 2026) |
BEAT |
pred ~$4.32 vs. cons $4.26 |
MEDIUM |
| PSA |
Report |
Same-Store Revenue Growth YoY (Q2 2026) |
BEAT |
pred ~-0.3% vs. cons -1.3% |
MEDIUM |
| PSA |
Report |
Same-Store NOI Growth YoY (Q2 2026) |
BEAT |
pred ~-0.8% vs. cons -2.0% |
MEDIUM |
| PSA |
Guide |
FY2026 Core FFO per share guidance (post-NSA) |
UNCHANGED |
guide ~$16.90 vs. cons $16.94 (FY2026) |
MEDIUM |
| PSA |
Guide |
FY2026 Same-Store Revenue growth guidance |
BETTER |
guide ~0.0% vs. cons -1.1% (FY2026, prior range midpoint) |
MEDIUM |
| PSA |
Guide |
FY2026 Same-Store NOI growth guidance |
BETTER |
guide ~-1.5% vs. cons -2.2% (FY2026, prior range midpoint) |
MEDIUM |
| PSA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.2% |
— |
MEDIUM |
| PSA |
Return |
5-day cumulative residual |
+0.3% (FADE) |
PSA has already rallied ~28% YTD into the print (near $330, close to Street mean target of $332), and management explicitly framed NSA as roughly FFO-neutral in 2026 (accretion of $0.10-$0.20 only arrives in 2027, $0.35-$0.50 at 2028-29 stabilization). Consensus FY26 Core FFO of ~$16.94 already sits near the top of the pre-NSA $16.35-$17.00 range, leaving little room for a dramatic raise; any reaffirm-rather-than-raise outcome, plus new pro-forma leverage/dilution details from the ~$900M debt raise and share issuance, gives analysts reason to trim out-quarter FFO/share estimates even after a same-store beat, causing the initial pop to partially fade over the week as the market digests integration/leverage complexity versus the cleaner EXR beat-and-raise the day before. |
LOW |